- Home
- CLDX vs ARVN Comparison
CLDX vs ARVN Comparison
Compare CLDX & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- ARVN
- Stock Information
- Founded
- CLDX 1983
- ARVN 2015
- Country
- CLDX United States
- ARVN United States
- Employees
- CLDX N/A
- ARVN N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- CLDX Health Care
- ARVN Health Care
- Exchange
- CLDX Nasdaq
- ARVN Nasdaq
- Market Cap
- CLDX 1.6B
- ARVN 1.4B
- IPO Year
- CLDX 2008
- ARVN 2018
- Fundamental
- Price
- CLDX $23.78
- ARVN $18.05
- Analyst Decision
- CLDX Buy
- ARVN Strong Buy
- Analyst Count
- CLDX 7
- ARVN 13
- Target Price
- CLDX $64.83
- ARVN $63.00
- AVG Volume (30 Days)
- CLDX 1.1M
- ARVN 907.0K
- Earning Date
- CLDX 02-24-2025
- ARVN 02-25-2025
- Dividend Yield
- CLDX N/A
- ARVN N/A
- EPS Growth
- CLDX N/A
- ARVN N/A
- EPS
- CLDX N/A
- ARVN N/A
- Revenue
- CLDX $9,976,000.00
- ARVN $161,100,000.00
- Revenue This Year
- CLDX N/A
- ARVN $239.85
- Revenue Next Year
- CLDX N/A
- ARVN N/A
- P/E Ratio
- CLDX N/A
- ARVN N/A
- Revenue Growth
- CLDX 128.55
- ARVN 1.07
- 52 Week Low
- CLDX $22.17
- ARVN $17.08
- 52 Week High
- CLDX $53.18
- ARVN $53.08
- Technical
- Relative Strength Index (RSI)
- CLDX 41.99
- ARVN 40.03
- Support Level
- CLDX $22.17
- ARVN $17.35
- Resistance Level
- CLDX $29.05
- ARVN $21.00
- Average True Range (ATR)
- CLDX 1.57
- ARVN 1.18
- MACD
- CLDX -0.26
- ARVN 0.06
- Stochastic Oscillator
- CLDX 23.40
- ARVN 24.74
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.